Insider Buying: Julie Brooks Purchases 1,122 Shares of Veracyte Stock (VCYT)
Veracyte (NASDAQ:VCYT) EVP Julie Brooks purchased 1,122 shares of Veracyte stock on the open market in a transaction that occurred on Tuesday, July 29th. The stock was purchased at an average cost of $14.69 per share, for a total transaction of $16,482.18. Following the purchase, the executive vice president now directly owns 3,122 shares in the company, valued at approximately $45,862. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on VCYT. Analysts at Janney Montgomery Scott initiated coverage on shares of Veracyte in a research note on Thursday, June 26th. They set a “buy” rating and a $25.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday, June 19th. They set an “overweight” rating and a $21.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $21.40.
Shares of Veracyte (NASDAQ:VCYT) opened at 14.93 on Thursday. Veracyte has a one year low of $10.88 and a one year high of $19.00. The stock has a 50-day moving average of $15.27 and a 200-day moving average of $15.09. The company’s market cap is $316.1 million.
Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the prior year, the company posted ($9.04) earnings per share. The company’s quarterly revenue was up 70.5% on a year-over-year basis. Analysts expect that Veracyte will post $-1.29 EPS for the current fiscal year.
Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.